EQS Newswire / 17/01/2025 / 10:07 UTC+8 The concept of value investing always withstands the test of time, and CK Life Sciences has demonstrated exceptional insight and wisdom in this area. As a flagship entity of the CKH Holdings in Hong Kong, CK Life Sciences (HKSE: 0775) made a pivotal investment in an IPO project ..read more

EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // January 15, 2025 Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar ..read more

Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results/Forecast Drägerwerk AG & Co. KGaA: Preliminary figures 2024: Net sales just below and earnings just above expectations – Forecast 2025 15-Jan-2025 / 19:55 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News ..read more

New York, 01/15/2025 / 09:15, EST/EDT – EQS Newswire – Laxxon Medical Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the successful results of its pilot nonclinical pharmacokinetic (PK) study for its innovative oral GLP-1 agonist weight loss tablet, LXM.2. Pilot PK data identified ..read more

Issuer: Goldinvest Consulting GmbH / Key word(s): Miscellaneous/Product Launch 15.01.2025 / 09:46 CET/CEST The issuer is solely responsible for the content of this announcement. Canadian biotech company Hemostemix (TSXV:HEM; FRA:2VF0) has confidently secured the registered trademark “your fountain of youth” (TM)[1]”). But what sounds like science fiction or mere marketing is not. Rather, this promise ..read more

EQS-News: Cantourage Group SE / Key word(s): Development of Sales Legalization of cannabis brings strong growth: Cantourage Group SE increases its sales by 118% to EUR 51.4 million in full year 2024 15.01.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Not for release, publication or distribution, directly or ..read more

EQS-News: BRAIN Biotech AG / Key word(s): Annual Report/Annual Results Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects 15.01.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash ..read more

Issuer: Goldinvest Consulting GmbH / Key word(s): Drilling Result/Miscellaneous 13.01.2025 / 08:25 CET/CEST The issuer is solely responsible for the content of this announcement. One of the ways in which the quality of an outstanding CEO is demonstrated is by recognizing opportunities and daring to do things that others simply lack the imagination to do ..read more

Eckert & Ziegler SE / Key word(s): Alliance Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture 14-Jan-2025 / 17:03 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group. The issuer is solely responsible ..read more

EQS-News: Heidelberg Pharma AG / Key word(s): Study Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma 13.01.2025 / 08:17 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study ..read more